Tamoxifen citrate, weißes Pulver
Lieferant: ICN Biomedicals
Tamoxifen has been shown to protect bone from estrogen-deficiency bone loss and lower plasma cholesterol in the rat. A 10 µM solution has exhibited fungicidal activity (optimal pH 7,5) against yeast cells of C. albicans. It has been implemented in liver carcinogenesis in rats.
Other actions of tamoxifen are: Reduction of plasma levels of insulin-like growth factor; Induction of cells surrounding cancer cells to secrete transforming growth factor b; Inhibition of membrane lipid peroxidation probably by decreasing membrane fluidity.
Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells.
Soluble in methanol (50 mg/ml with heat) or ethanol (10 mg/ml with sonication); very slightly soluble in water (0,3 mg/L at 20 °C; the pH is approximately 3,0 to 3,5), 0,02 N HCl (0,2 mg/ml at 37 °C), acetone or chloroform.
|
Formel:
C₂₆H₂₉NO MW: 563,65 g/mol |
MDL Number:
MFCD00058321 CAS-Nummer: 54965-24-1 |
Learn more
About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...